Impact of Vision Impairment Scale
Also known as: IVI, Impact Vision Impairment
The Impact of Vision Impairment (IVI) scale is a quality-of-life instrument designed specifically for patients with significant vision loss (low vision) to measure the psychological, functional, and social burden of visual impairment. Developed by Wolffsohn, Cochrane, and colleagues (2000), the IVI captures domains including emotional impact (distress, frustration), functional limitations (mobility, ADLs), social participation, and role fulfillment in populations with moderate to severe vision loss where generic or mild-vision-focused instruments are insensitive.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Appropriate for any patient with low vision (acuity <20/60 Snellen or visual field <20°) from any cause (macular degeneration, retinitis pigmentosa, optic neuropathy, advanced glaucoma, severe diabetic retinopathy, corneal scarring, etc.). Baseline assessment at low vision rehabilitation intake documents starting burden. Repeat at 4–6 week, 3-month, and 6-month intervals to track emotional, functional, and social progress through rehabilitation. Particularly valuable when patient's disability and distress seem disproportionate to objective acuity, suggesting significant psychosocial component warranting counseling or group support.
Strengths & limitations
- Low vision-specific: designed for and validated in populations with moderate-to-severe vision loss, where generic vision scales show floor effects or miss key domains
- Multidimensional: captures functional, emotional, social, and role dimensions of low vision impact, not just activity limitation but existential and psychological burden
- Responsive to rehabilitation: documents meaningful improvements in emotional well-being, independence, and social participation after adaptive training and aids
- Addresses often-neglected domains: explicitly measures grief, frustration, social withdrawal, and identity concerns central to low vision experience but absent from activity-based instruments
- Validated in diverse low vision populations: tested across multiple etiologies (AMD, RP, optic neuropathy, etc.) and ages, with good reliability and responsiveness
- Requires substantial vision or adaptations to administer: self-report reading small text difficult in low vision; telephone or large-print/audio administration needed, increasing burden
- Variability in versions and scoring: multiple IVI/LVQOL variants exist with different item counts, subscale structures, and conversion formulas—not all published papers use identical instruments
- Limited cross-cultural validation: less extensively translated and validated globally compared to VFQ-25; norms vary by region and healthcare system
- Does not capture adaptive resilience or positive aspects: measures burden and limitation but not growth, acceptance, or meaningful adaptation some low vision patients achieve
- Heterogeneous low vision populations: AMD patients (usually older, slower onset) have different QoL trajectories than young retinitis pigmentosa patients (young, progressive, genetic); single IVI score may obscure these differences
Frequently asked
How does IVI differ from the NEI-VFQ-25 in low vision populations?
VFQ-25 is designed for broader vision loss across all severities and shows floor effects (many low-vision patients score near zero, losing discriminant power). IVI is specifically designed for low vision (acuity <20/60) and includes emotional, social, and existential domains (e.g., grief, identity, role loss) not captured in VFQ-25. In low vision rehabilitation, IVI is more responsive to change from counseling and aids. Many programs use both for comprehensive assessment.
What IVI score change indicates meaningful improvement from rehabilitation?
MCID is typically 5–10 points depending on subscale and version. Clinically, improvement of 10–20 points on a subscale over 3–6 months of rehabilitation (adaptive aids, skills training, counseling) indicates substantial benefit. Emotional domain improvements of 10+ points suggest reduced distress; Social domain improvements indicate restored participation.
Can IVI be used in completely blind patients (no light perception)?
IVI can be adapted for blindness, but many items reference vision loss rather than absence of vision; floor effects occur. In total blindness, orientation & mobility outcomes, independence in ADLs, and psychosocial measures (depression, social participation) are more interpretable than vision-specific QoL scores. Consider blindness-specific instruments (e.g., Functioning Everyday with a Visual Impairment scale) in this population.
Is IVI proprietary, and can clinicians use it freely?
IVI is not proprietary; freely available for clinical and research use. Always cite Wolffsohn & Cochrane (2000) in publications. Some extended versions or validated translations may have minor restrictions; check the published validation paper for your target version/language.
Sources
- Wolffsohn, J. S., & Cochrane, A. L. (2000). Design of the low vision quality-of-life questionnaire (LVQOL) and measurment of its item and scale validity and reliability. Optometry & Vision Science, 77(3), 144-152. link ↗
- Owsley, C., McGwin, G., & Scilley, K. (2007). The VisionCare Study: design and methods. Curr Eye Res, 32(4), 325-332. link ↗
How to cite this page
ScholarGate. (2026, June 3). Impact of Vision Impairment Scale. ScholarGate. https://scholargate.app/en/ophthalmology/impact-vision-impairment
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- GQL-15Ophthalmology↔ compare
- LVQOLOphthalmology↔ compare
- NEI-VFQ-25Ophthalmology↔ compare
- VF-14Ophthalmology↔ compare